US drug firms are to increase prices next year after an undertaking to delay increases expired. Mr Read’s comments suggest that Pfizer will aspire to resume normal growth trends. The companies will raise the price of their drugs by up to 30% in some cases and have been given until March 2016 to do so. Global prices dipped by 2% in Q3 and big pharma will be seeking to make up for any lost growth. Congressional hearings on drug costs are due next year, which may affect companies' ability to raise prices.
US drug firms are to increase prices next year after an undertaking to delay increases expired. The companies will raise the price of their drugs by up to 30% in some cases and have been given until March 2016 to do so. Global prices dipped by 2% in Q3 and big pharma will be seeking to make up for any lost growth. Congressional hearings on drug costs are due next year, which may affect companies' ability to raise prices.